ARTICLE | Product Development
Collaborating against the challenges of COVID, a conversation with Novartis’ R&D heads
R&D heads John Tsai and Jay Bradner discuss Novartis’ COVID-19 initiatives in a pair of BioCentury podcasts
May 14, 2020 1:15 AM UTC
In the latest BioCentury This Week -- Special Report podcasts, Novartis R&D heads John Tsai and Jay Bradner discuss with BioCentury the challenges facing drug developers as they attempt to develop countermeasures against COVID-19, and provide an insider’s view of how a coalition of more than a dozen of the world’s biggest pharmas is working together to develop therapies and vaccines.
The two Novartis AG (NYSE:NVS; SIX:NOVN) executives provide a behind-the-scenes look at how companies that are typically fierce competitors are collaborating in unprecedented ways, openly sharing compounds, research strategies, data and ideas (see “COVID R&D: Pharmas Align”). ...